B
Bruce E. Johnson
Researcher at Harvard University
Publications - 523
Citations - 76494
Bruce E. Johnson is an academic researcher from Harvard University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 104, co-authored 474 publications receiving 68801 citations. Previous affiliations of Bruce E. Johnson include University of Adelaide & Virginia Tech.
Papers
More filters
Journal ArticleDOI
OA13.07 Neoadjuvant Atezolizumab in Resectable NSCLC Patients: Immunophenotyping Results from the Interim Analysis of the Multicenter Trial LCMC3
Filiz Oezkan,Kai He,Dwight H. Owen,Maciej Pietrzak,J.H. Cho,Rhonda Kitzler,Rebecca Pearson,V. Rusch,Jamie E. Chaft,Robert D. Suh,Justin D. Blasberg,Karen L. Reckamp,Dan J. Raz,Peter J. Kneuertz,L. Fiorillo,Edward B. Garon,Alan Nicholas,A. Johnson,Katja Schulze,J. Grindheim,R. Banchereau,S. Phan,Paul A. Bunn,David J. Kwiatkowski,Bruce E. Johnson,Mark G. Kris,I. I. Wistuba,J.M. Lee,Gerard Lozanski,David P. Carbone +29 more
Journal ArticleDOI
A G-to-A Single Nucleotide Polymorphism in intron 2 of the human CACNA2D2 gene that maps at 3p21.3.
TL;DR: This SNP is informative with regard to LOH investigation in cancer omic DNA, 12·5 pmol of each primer, 200 M dNTPs, 1·5 mM MgCl2,1·25 nCi 35S-dATP, and no biased loss of one allele over the other was observed.
Journal ArticleDOI
Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing
Adem Albayrak,Ana C. Garrido-Castro,Marios Giannakis,Marios Giannakis,Renato Umeton,Renato Umeton,Monica Devi Manam,Elizabeth H. Stover,Rebecca L. Porter,Bruce E. Johnson,Kai-Li Liaw,Mayur Amonkar,Alanna J. Church,Alanna J. Church,Katherine A. Janeway,Jonathan A. Nowak,Jonathan A. Nowak,Lynette M. Sholl,Lynette M. Sholl,Nan Lin,Jason M. Johnson +20 more
TL;DR: Patients with mismatch repair–deficient cancers agnostic to tumor type are recruited for clinical trials of immune checkpoint inhibitors, which promise the potential to transform the treatment of these cancers into a “drug-free” condition.
Journal ArticleDOI
Success of genomic profiling of non-small cell lung cancer biopsies obtained by trans-thoracic percutaneous needle biopsy.
Ritu R. Gill,David J. Murphy,Sasha Kravets,Lynnette Mary Sholl,Pasi A. Jänne,Bruce E. Johnson +5 more
TL;DR: The success of genomic profiling of non–small cell lung cancer (NSCLC) obtained by trans‐thoracic needle biopsy (TTNB) in a single center experience is reported.
Journal ArticleDOI
Correlative analyses of plasma cytokine/angiogenic factor (C/AF) profile, gender and outcome in a randomized, three-arm, phase II trial of first-line vandetanib (VAN) and/or carboplatin plus paclitaxel (CP) for advanced non-small cell lung cancer (NSCLC)
Emer O. Hanrahan,Heather Lin,D. Z. Du,Shaoyu Yan,Edward S. Kim,J. Jack Lee,Anderson J. Ryan,Hai T. Tran,Bruce E. Johnson,John V. Heymach +9 more
TL;DR: In this paper, a phase II trial, 181 patients with advanced NSCLC were randomized to 1st-line treatment with VAN, CP, or VAN + CP.